药品名:Telomelysin 其他名称:OBP-301 研发方:Oncolys BioPharma 咨询方:港安健康国际医疗 Telomelysin国际研究情况 2019年美国癌症研究协会(AACR)年会上,一项关于Telomelysin联合放射治疗的开放标签、I期剂量递增研究(UMIN 000010158)数据公布。该研究入组13例经组织活检证实为不适合标准手术治疗或化疗的患者。研究治疗...
4052 Background: OBP-301 is a novel, replication-selective adenoviral construct that incorporates the human telomerase reverse transcriptase gene (hTERT) promoter, which is highly expressed in tumors but not in normal, differentiated adult cells, to regulate expression of the early adenoviral genes, ...
6 月 9 日,恒瑞发布公告,已与日本 Oncolys 公司协商一致,决定终止有关溶瘤腺病毒产品 TelomelysinTM(OBP-301)的相关合作并签署了终止协议。 在 2016 年 12 月 2 日,恒瑞与日本 Oncolys BioPharma 公司达成协议,有偿获得 Oncolys 研发的溶瘤腺病毒产品 Telomelysin(OBP-301) 在中国大陆、香港...
P1-154: Antitumor effect of Telomerase-Selective Oncolytic Adenoviral Agent OBP-301 (Telomelysin) in pleural dissemination of human malignant mesotheliomaP1-154: Antitumor effect of Telomerase-Selective Oncolytic Adenoviral Agent OBP-301 (Telomelysin) in pleural dissemination of human malignant mesot...
亿欧大健康6月9日讯,恒瑞医药发布公告称,公司与日本Oncolys公司协商一致,决定终止有关溶瘤腺病毒产品TelomelysinTM(OBP-301)的相关合作并签署了终止协议。原合作协议于2016年11月30日由本公司与日本Oncolys 公司达成,恒瑞医药有偿获得日本 Oncolys 公司研发的溶瘤腺病毒产品TelomelysinTM(OBP-301)在中国大陆、香港和...
Patients received OBP-301 at 2x1012 viral particles via direct tumor injection every two weeks x 4 injections as well as pembrolizumab 200 mg IV every 3 weeks. The primary endpoint was objective response rate (ORR). The null hypothesis that the ORR is < 15% was tested against the Ha ORR...
Telomelysin (OBP-301) is a telomerase-specific replication-component adenovirus. Telomelysin has a human telomerase reverse transcriptase (hTERT) promoter element which efficiently kills human cancer cells, but not normal cells. The present study investigated the correlation betweenthe antitumor effect ...
Telomelysin (OBP-301) is a telomerase-specific replication-competent adenovirus with a human telomerase reverse transcriptase (hTERT) promoter. Telomelysin has a strong antitumor effect on a variety of cancers, including head and neck squamous cell carcinoma (HNSCC), and combining telomelysin ...
(2009). Antiviral activity of cidofovir against telomerase-specific replication-selective oncolytic adenovirus, OBP-301 (Telomelysin), Invest. New Drugs 27(3):241-245.Ouchi, M., Kawamura, H., Urata, Y., Fujiwara, T., 2009. Antiviral activity of cidofovir against telomerase-specific replication...
Human head and neck squamous cell carcinoma (HNSCC) cell lines and a murine HNSCC\n(NR-S1) model were used to investigate whether telomelysin (OBP-301) had a therapeutic efficacy for HNSCC. We examined the cell killing effects of telomelysin and the induction of tumor cell apoptosis by ...